Neuroendocrine carcinoma

6 trials 4 recruiting MedDRA PT
6 Registered trials
4 Recruiting
4 Unique sponsors
7 Unique IMPs
2 Commercial trials
Drug classes (ATC)
— ATC code not specified 3
V Various (ATC V) 2
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 5 substances
Monoclonal antibody 1 substance
Kinase inhibitor 1 substance
Phase II: 5 Phase I (Other): 1

Filter these 6 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 6 trials

Phase II

5 trials
  • Boehringer Ingelheim International GmbH Commercial
    BI 764532; IGG-LIKE T CELL ENGAGER BINDING TO DLL3 AND CD3
    2023-504247-13-00 8 countries 2023 n=122 Orphan
    Recruiting
  • Istituto Europeo Di Oncologia S.r.l. Academic
    IMP not specified
    2024-510898-24-00 1 country 2022 n=46
    Recruiting
  • Rigshospitalet Academic
    FLUDEOXYGLUCOSE (18F); PYRUVIC ACID
    2024-516131-28-00 1 country 2022 n=15
    Recruiting
  • Rigshospitalet Academic
    DOTATATE, COPPER (64CU) CHLORIDE; FLUDEOXYGLUCOSE (18F)
    2024-516156-18-00 1 country 2023 n=200
    Recruiting
  • Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR Academic
    AVELUMAB; CABOZANTINIB
    2024-513518-37-00 1 country 2022 n=30
    Ended

Phase I (Other)

1 trial
  • Boehringer Ingelheim International GmbH Commercial
    IMP not specified
    2023-505870-13-00 6 countries 2024 n=35
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Boehringer Ingelheim International GmbH Commercial 2 Phase I (Other), Phase II 1
Rigshospitalet Academic 2 Phase II 2
Istituto Europeo Di Oncologia S.r.l. Academic 1 Phase II 1
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR Academic 1 Phase II 0
New trials by year
2022
3
2023
2
2024
1
← All indication landscapes